Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the average daily volume of 53 put options.
Maravai LifeSciences Price Performance
Shares of NASDAQ MRVI opened at $8.42 on Thursday. Maravai LifeSciences has a twelve month low of $4.52 and a twelve month high of $16.62. The firm has a market cap of $2.12 billion, a P/E ratio of -9.36 and a beta of 0.01. The company has a 50 day moving average of $7.89 and a 200 day moving average of $6.66. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. The firm had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. As a group, research analysts expect that Maravai LifeSciences will post -0.15 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Maravai LifeSciences
Hedge Funds Weigh In On Maravai LifeSciences
A number of hedge funds have recently added to or reduced their stakes in the company. Glenmede Trust Co. NA grew its position in Maravai LifeSciences by 163.8% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,108,554 shares of the company’s stock worth $11,086,000 after purchasing an additional 688,403 shares during the period. Hudson Bay Capital Management LP grew its position in Maravai LifeSciences by 171.9% in the 3rd quarter. Hudson Bay Capital Management LP now owns 659,397 shares of the company’s stock worth $6,594,000 after purchasing an additional 416,876 shares during the period. Mesirow Institutional Investment Management Inc. grew its position in Maravai LifeSciences by 33.6% in the 3rd quarter. Mesirow Institutional Investment Management Inc. now owns 926,277 shares of the company’s stock worth $9,263,000 after purchasing an additional 232,901 shares during the period. Kennedy Capital Management LLC bought a new stake in Maravai LifeSciences in the 3rd quarter worth approximately $1,047,000. Finally, Seven Eight Capital LP bought a new stake in Maravai LifeSciences in the 3rd quarter worth approximately $172,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Stories
- Five stocks we like better than Maravai LifeSciences
- Roth IRA Calculator: Calculate Your Potential Returns
- AMD is Down 35%. Now is the Time to Buy the Dip
- 3 Monster Growth Stocks to Buy Now
- Amazon Stands Tall: New Highs Are in Sight
- Transportation Stocks Investing
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.